GB Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBLX research report →
Companywww.gbsciences.com
GB Sciences, Inc. engages in the research and development of plant-based medicines in North America and Europe. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market.
- CEO
- Andrea Small-Howard
- IPO
- 2008
- Employees
- 2
- HQ
- Las Vegas, NV, US
Price Chart
Valuation
- Market Cap
- $162.83K
- P/E
- -0.12
- P/S
- 0.00
- P/B
- -0.03
- EV/EBITDA
- -1.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 28.02%
- ROIC
- 39.97%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,362,000 · 66.98%
- EPS
- $-0.00 · 64.35%
- Op Income
- $-1,421,000
- FCF YoY
- 37.40%
Performance & Tape
- 52W High
- $0.50
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 9.86
- Avg Volume
- 41.72K
Get TickerSpark's AI analysis on GBLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 18 | POSS JOHN C | buy | 3,615 |
| Jul 11, 18 | POSS JOHN C | buy | 11,915 |
| Jul 11, 18 | POSS JOHN C | buy | 20,000 |
| Jul 11, 18 | POSS JOHN C | buy | 1,250 |
| Jul 11, 18 | POSS JOHN C | buy | 30,000 |
| Jul 11, 18 | POSS JOHN C | buy | 23,184 |
| Jul 11, 18 | POSS JOHN C | buy | 10,000 |
| Aug 10, 15 | POSS JOHN C | other | 0 |
| Nov 27, 17 | POSS JOHN C | other | 937,500 |
| Jun 1, 16 | POSS JOHN C | other | 1,400,000 |
Our GBLX Coverage
We haven't published any research on GBLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GBLX Report →